This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Pantoprazole parenteral

Updated 2 Feb 2023 | Proton pump inhibitors


Powder for solution for injection containing pantoprazole.

Drugs List

  • pantoprazole 40mg powder for solution for injection
  • PROTIUM IV 40mg powder for solution for injection
  • Therapeutic Indications


    Benign gastric and duodenal ulceration
    Reflux oesophagitis
    Zollinger-Ellison syndrome (and other hypersecretory conditions)


    This product should be administered by a healthcare professional and under appropriate medical supervision.

    Pantoprazole injection should be used only when the oral route is not appropriate.

    Data are available on intravenous use for up to 7 days. Transition from intravenous to oral formulation should be performed as soon as clinically justified.


    Duodenal ulcer, gastric ulcer, reflux oesophagitis
    40mg intravenously daily.

    Zollinger-Ellison Syndrome and other pathological hypersecretory conditions
    Initially 80mg daily. Following this, the dosage may be titrated up or down as required based on measurement of gastric acid secretion. Daily doses above 80mg should be given in 2 divided doses. A temporary increase in dose above 160mg daily is possible but should not be administered for longer than is required for adequate acid secretion control.

    If rapid acid control is required a starting dose of 160mg can be administered.

    Patients with Hepatic Impairment

    In patients with severe hepatic impairment the daily dose should be reduced to 20mg pantoprazole.


    Administer by intravenous injection or infusion only.

    Duration of administration should be 2 to 15 minutes, by slow injection or further diluted and administered as a short-term infusion.


    Children under 18 years
    Long QT syndrome
    Torsade de pointes

    Precautions and Warnings

    Family history of long QT syndrome
    Electrolyte imbalance
    History of torsade de pointes
    Severe hepatic impairment

    Correct electrolyte disorders before treatment
    Advise patient blurred vision may affect ability to drive/operate machinery
    Advise patient dizziness may affect ability to drive or operate machinery
    Exclude malignancy, if alarm symptoms develop in presence of gastric ulcer
    Measure magnesium levels before and periodically during prolonged treatment
    Consider monitoring ECG in patients at risk of QT prolongation
    Ensure adequate vitamin D & calcium in patients at risk of osteoporosis
    Monitor serum electrolytes
    Consider discontinuing if subacute cutaneous lupus erythematosus occurs
    Increased risk of GI infection due to decreased gastric acidity
    May interfere with certain laboratory measurements
    Discontinue if there is a rise in liver enzymes
    Advise patient not to take St John's wort concurrently
    Advise patient to avoid sun exposure if subacute lupus erythematosus occurs

    Prolonged use (greater than 1 year) of proton pump inhibitors has been associated with hypomagnesaemia. Patient should seek medical advice if symptoms of hypomagnesaemia occur (e.g. muscle twitches, tremors, vomiting, tiredness, loss of appetite) while taking pantoprazole.

    Prolonged use (greater than 1 year) of PPIs has been associated with an increased risk of hip, wrist and spine fracture, predominantly in the elderly or in the presence of other recognised risk factors.

    Rebound acid hypersecretion and protracted dyspepsia may occur after stopping prolonged treatment with a PPI.

    Very infrequent cases of subacute cutaneous lupus erythematosus (SCLE) have been reported in patients taking PPIs. Drug-induced SCLE can occur weeks, months or even years after exposure to the drug. The MHRA have issued the following advice if a patient treated with a PPI develops lesions - especially in sun-exposed areas of the skin - and it is accompanied by arthralgia:

    - advise them to avoid exposing the skin to sunlight.
    - consider SCLE as a possible diagnosis.
    - consider stopping use of the PPI unless it is imperative for a serious acid-related condition; a patient who develops SCLE with a particular PPI may be at risk of the same reaction with another.
    - in most cases, symptoms resolve on PPI withdrawal; topical or systemic steroids might be necessary for treatment of SCLE only if there are no signs of remission after a few weeks or months.

    Pregnancy and Lactation


    Pantoprazole should be used with caution during pregnancy.

    The animal and limited human data suggests that pantoprazole represents a low risk in pregnancy.

    Animal reproduction studies have revealed signs of slight foetotoxicity at doses above 5mg/kg.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Pantoprazole should be used with caution during breastfeeding.

    There is limited information about the safety of pantoprazole during breastfeeding in humans but excretion in breast milk has been reported.

    Pantoprazole doses of 40mg daily produce low levels in milk and would not be expected to cause any adverse effects in breast fed infants (LactMed).

    As with all the PPIs, pantoprazole is completely unstable in an acid milieu and when present in milk, it would be largely destroyed before absorption (Hale, 2014).

    Schaefer recommends that if a PPI is indicated, omeprazole or pantoprazole should be chosen.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at


    Advise patient to seek medical advice if symptoms of hypomagnesaemia occur (e.g. muscle twitches, tremors, vomiting, tiredness, loss of appetite) while taking pantoprazole.

    Side Effects

    Abdominal distension
    Anaphylactic shock
    Anaphylactoid reaction
    Blurred vision
    Dry mouth
    Elevated triglyceride levels
    Erythema multiforme
    Fundic gland polyps (benign)
    Gamma glutamyl transferase (GGT) increased
    Hepatic failure
    Hypersensitivity reactions
    Increase in plasma cholesterol
    Increase of liver transaminases
    Increased risk of fractures
    Interstitial nephritis
    Lyell's syndrome
    Muscle spasm
    Peripheral oedema
    Renal failure
    Rise in body temperature
    Severe hepatocellular damage
    Sleep disturbances
    Stevens-Johnson syndrome
    Subacute cutaneous lupus erythematosus
    Taste disturbances
    Thrombophlebitis (injection site)
    Upper abdominal pain
    Visual disturbances
    Weight changes

    Effects on Laboratory Tests

    Treatment with pantoprazole may increase Chromogranin A (CgA) levels and may therefore interfere with investigations for neuroendocrine tumours. To avoid this, stop pantoprazole treatment temporarily for at least five days before CgA measurements. After initial measurement, if CgA and gastrin levels have not returned to reference range, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: May 2017

    Reference Sources

    Available at:
    Last accessed: 21 October, 2014

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Joint Formulary Committee. British National Formulary. 73rd ed. London: BMJ Group and Pharmaceutical Press; 2017.

    Medications and Mothers' Milk, Sixteenth Edition (2014) Hale, T and Rowe, H, Hale Publishing, Plano, Texas.

    MHRA Drug Safety Update April 2012. Proton pump inhibitors in long-term use: increased risk of fracture.
    Available at:
    Last accessed: 5 May 2017

    MHRA Drug Safety Update September 2015. Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus.
    Available at:
    Last accessed: 5 May 2017

    Summary of Product Characteristics: Protium 40mg i.v. Powder for Solution for Injection. Takeda UK Ltd. Revised March 2017.

    Summary of Product Characteristics: Pantoprazole 40mg powder for solution for injection. Sandoz Limited. Revised February 2017.

    Summary of Product Characteristics: Pantoprazole 40mg powder for solution for injection. Ranbaxy (UK) Limited a Sun Pharmaceutical Company. Revised May 2018.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Pantoprazole Last revised: 5 May 2017
    Last accessed: 5 May 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.